| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | Medicines for the treatment of 1st stage African trypanosomiasis |
Others observations: (as isetionate) in vial To be used for the treatment of Trypanosoma brucei gambiense infection. |
| Bolivia | LINAME 2011 - 2013 | No observations |
| List | Section | Observation |
|---|---|---|
| Bolivia | LINAME 2011 - 2013 | No observations |
| List | Section | Observation |
|---|---|---|
| PAHO Strategic Fund Medicine List | 2.7.1. Antileishmaniasis medicines |
Others observations: This medicine should be used in accordance with the recommendations outlined in the Leishmaniasis in the Americas: Recommendations for the treatment (2013) guide. |
| Cuba | 6.1.1.3 AntileishmaniƔsicos y antitripanosomiƔsicos | No observations |
| List | Section | Observation |
|---|---|---|
| Colombia | 2.0 AIDS | No observations |
| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | 6.5.4. Antipneumocystosis and antitoxoplasmosis medicines | No observations |
| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | 6.5.4. Antipneumocystosis and antitoxoplasmosis medicines | No observations |
| List | Section | Observation |
|---|---|---|
| PAHO Strategic Fund Medicine List | 2.7.3. Antipneumocystosis and antitoxoplasmosis medicines | No observations |
| List | Section | Observation |
|---|---|---|
| PAHO Strategic Fund Medicine List | 2.7.3. Antipneumocystosis and antitoxoplasmosis medicines | No observations |